< RIPK1 as a therapeutic target >
serine/threonine-protein kinase 1) activation in microglia
astrocytes drives a response to
RIPK1 is a critical signaling protein
in the tumor necrosis factor (TNF)
receptor pathway and
is a regulator of inflammation and cell death.
RIPK1 kinase emerged the possibility to target neuroinflammation and
cell death which
neurologic conditions including Alzheimer, ALS, and multiple
▣ BiSiChem has currently the following programs
in development :
• BSC-3301 is an orally bioavailable,
highly potent and selective, and achieving a high extent of brain-penetrating
small molecule inhibitor in CNS diseases. RIPK1 is highly expressed by
microglial cells in human AD brains.
In vivo 5XFAD model, we found that
inhibition of RIPK1, using small molecule inhibitor, reduced
the levels of
inflammatory cytokines and cognitive deficits.
• Non-brain penetrating RIPK1
inhibitor : BSC-1301 is an orally bioavailable small molecule for
the treatment of autoimmune
diseases including psoriasis, rheumatoid arthritis (RA) and ulcerative colitis.